| Haller, Michael J |
| Active, not recruiting | 3 | 319 | US | Afrezza, Technosphere Insulin, Rapid-acting Insulin Analog, insulin aspart, insulin lispro, insulin glulisine, Novolog®, Fiasp®, Humalog®, Admelog®, Apidra®, Basal Insulin, insulin glargine, insulin degludec, insulin detemir, Lantus®, Abasaglar®, Basaglar®, Semglee®, Toujeo®, Tresiba®, Levemir® | Mannkind Corporation, Jaeb Center for Health Research | Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | 10/24 | 05/25 | | |
NCT05743244: Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D) |
|
|
| Recruiting | 2 | 78 | US | Abrocitinib 200 MG Oral Tablet, CIBINQO, Ritlecitinib, Placebo | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Pfizer | Diabetes Mellitus, Type 1 | 06/26 | 06/27 | | |
TOPPLE T1D, NCT04279613: A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041 |
|
|
| Completed | 1 | 47 | US | NNC0361-0041, Placebo | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Novo Nordisk A/S | Type I Diabetes | 08/23 | 04/24 | | |
NCT06719531: SYNERGY PLUS: Evaluation of Next Generation Sensors (NGS) and Algorithm in Patients with Type 1 and Type 2 Diabetes |
|
|
| Not yet recruiting | N/A | 1500 | US | Continuous Glucose Monitoring | Medtronic Diabetes | Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus | 12/25 | 12/25 | | |
| Jones, Thomas I |
NCT05706506: A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2) |
|
|
| Completed | 4 | 152 | US | Tirzepatide, LY3298176 | Eli Lilly and Company | Type 2 Diabetes, Diabetes Mellitus, Type 2 | 10/23 | 10/23 | | |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) |
|
|
| Recruiting | 3 | 10000 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD) | 02/29 | 02/29 | | |
QWINT-5, NCT05463744: A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy |
|
|
| Completed | 3 | 692 | Europe, Japan, US, RoW | Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec | Eli Lilly and Company | Type 1 Diabetes, Diabetes | 05/24 | 05/24 | | |
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk |
|
|
| Active, not recruiting | 3 | 2749 | Europe, US, RoW | Orforglipron, LY3502970, Insulin Glargine | Eli Lilly and Company | Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease | 09/25 | 01/26 | | |
ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities |
|
|
| Active, not recruiting | 3 | 3000 | Europe, Japan, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | Obesity, Overweight, Overweight or Obesity | 07/25 | 07/27 | | |
ZONE, NCT05762107: A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes |
|
|
| Recruiting | 2 | 186 | Canada, US | Placebo, ZT-01, 7 mg, ZT-01, 15 mg, ZT-01, 22 mg | Zucara Therapeutics Inc. | Type 1 Diabetes Mellitus with Hypoglycemia | 06/25 | 07/25 | | |
| Recruiting | N/A | 250 | Europe, US | reSept ASD Occluder | atHeart Medical | Heart Septal Defect, Heart Septal Defects, Atrial, Heart Defects, Congenital, Cardiovascular Abnormalities, Cardiovascular Diseases, Heart Diseases, Congenital Abnormalities | 12/26 | 12/30 | | |
NCT05325294: Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adults and Pediatrics Utilizing Lyumjev® |
|
|
| Completed | N/A | 244 | US | MiniMed 780G System | Medtronic Diabetes, Eli Lilly and Company | Type 1 Diabetes | 01/24 | 01/24 | | |
NCT05238142: In-Home Study with MiniMed™ 780G Pump Automated Control in Type 2-Evaluation of the AHCL System in Adults with Insulin-requiring Type 2 Diabetes |
|
|
| Active, not recruiting | N/A | 575 | US | MiniMed™ 780G Insulin Pump system | Medtronic Diabetes | Type 2 Diabetes Treated with Insulin | 01/25 | 02/25 | | |
| Bode, Bruce |
MKC-TI-193, NCT05904743: INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes |
|
|
| Completed | 4 | 141 | US | Afrezza, Technosphere Insulin, insulin degludec, Rapid-acting Insulin Analog, any FDA approved Rapid-acting Insulin Analog, Basal Insulin, any FDA approved Basal Insulin | Mannkind Corporation, Jaeb Center for Health Research | Diabetes Mellitus, Type 1 | 03/24 | 06/24 | | |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) |
|
|
| Recruiting | 3 | 10000 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD) | 02/29 | 02/29 | | |
OPTI-2, NCT06238778: Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec |
|
|
| Recruiting | 2 | 230 | US | HDV-Lispro, HDV-L, Lispro, LIS | Diasome Pharmaceuticlas, Inc. | Diabetes Mellitus, Type 1 | 06/25 | 12/25 | | |
| Completed | 2 | 265 | Europe, Canada, US, RoW | INV-202, None applicable, Placebo | Inversago Pharma Inc., Worldwide Clinical Trials | Diabetic Kidney Disease | 08/24 | 09/24 | | |
| Active, not recruiting | 2 | 140 | Europe, US, RoW | Ladarixin, allosteric inhibitor of CXCL8 (IL-8), CXCR1 and CXCR2 receptors, Placebo | Dompé Farmaceutici S.p.A, Dompe farmaceutici s.p.a. | Recent Onset type1 Diabetes | 04/24 | 04/26 | | |
| Recruiting | N/A | 20 | US | Experimental prospective single arm evaluating the Medtronic Duo Extended Set, Medtronic DUO Extended Set with 670G Pump Therapy | Atlanta Diabetes Associates, Medtronic | Diabetes Mellitus, Type 1 | 10/21 | 11/21 | | |
NCT04809285: Use of the Guardian™ Connect System With Smart Connected Devices |
|
|
| Completed | N/A | 217 | US | Guardian™ Connect system, InPen™ Basal smart cap, smart insulin pens, and InPen™ Diabetes Management app | Medtronic Diabetes | Type 1 Diabetes Mellitus | 09/23 | 09/23 | | |
NCT05325294: Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adults and Pediatrics Utilizing Lyumjev® |
|
|
| Completed | N/A | 244 | US | MiniMed 780G System | Medtronic Diabetes, Eli Lilly and Company | Type 1 Diabetes | 01/24 | 01/24 | | |
NCT05714059: Safety and Effectiveness of the MiniMed™ 780G System With DS5 CGM |
|
|
| Completed | N/A | 250 | US | Insulin Pump with Continuous Glucose Monitoring | Medtronic Diabetes | Type 1 Diabetes | 12/23 | 12/23 | | |
NCT05908448: The True Vie I3 Continuous Glucose Monitoring System in Pediatric Patients With Type 1 Diabetes Mellitus |
|
|
| Completed | N/A | 134 | US | 13 CGM (continuous glucose monitor) | Sinocare, Atlanta Diabetes Associates | T1DM - Type 1 Diabetes Mellitus | 10/24 | 11/24 | | |
NCT05238142: In-Home Study with MiniMed™ 780G Pump Automated Control in Type 2-Evaluation of the AHCL System in Adults with Insulin-requiring Type 2 Diabetes |
|
|
| Active, not recruiting | N/A | 575 | US | MiniMed™ 780G Insulin Pump system | Medtronic Diabetes | Type 2 Diabetes Treated with Insulin | 01/25 | 02/25 | | |
NCT05224258: Evaluation of the MiniMed™ 780G System in Type 1 Adult and Pediatric Subjects Utilizing Insulin Fiasp® |
|
|
| Completed | N/A | 240 | Canada, US, RoW | MiniMed 780G System | Medtronic Diabetes | Type 1 Diabetes | 06/24 | 06/24 | | |
NCT06719531: SYNERGY PLUS: Evaluation of Next Generation Sensors (NGS) and Algorithm in Patients with Type 1 and Type 2 Diabetes |
|
|
| Not yet recruiting | N/A | 1500 | US | Continuous Glucose Monitoring | Medtronic Diabetes | Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus | 12/25 | 12/25 | | |
| Recruiting | N/A | 925 | US | Blood glucose meter, Eversense CGM System | Senseonics, Inc. | Diabetes | 03/26 | 03/26 | | |
| Laffel, Lori |
| Active, not recruiting | 3 | 319 | US | Afrezza, Technosphere Insulin, Rapid-acting Insulin Analog, insulin aspart, insulin lispro, insulin glulisine, Novolog®, Fiasp®, Humalog®, Admelog®, Apidra®, Basal Insulin, insulin glargine, insulin degludec, insulin detemir, Lantus®, Abasaglar®, Basaglar®, Semglee®, Toujeo®, Tresiba®, Levemir® | Mannkind Corporation, Jaeb Center for Health Research | Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | 10/24 | 05/25 | | |
NCT06362265: A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus |
|
|
| Recruiting | 1 | 22 | US | LY3209590 | Eli Lilly and Company | Type 2 Diabetes Mellitus | 11/26 | 11/26 | | |
NCT05403502: Safety Evaluation of an Advanced Hybrid Closed Loop System Using Lyumjev With the Tandem t:Slim X2 Insulin Pump With Control-IQ Technology in Adults, Adolescents and Children With Type 1 Diabetes |
|
|
| Completed | N/A | 183 | US | t:slim X2 insulin pump with Control-IQ technology 1.5 | Tandem Diabetes Care, Inc., Eli Lilly and Company, Jaeb Center for Health Research | Type 1 Diabetes | 08/23 | 08/23 | | |
NCT05683392: Use of Control-IQ Technology 2.0 in Adults, Children, and Preschoolers With Type 1 Diabetes |
|
|
| Completed | N/A | 72 | US | t:slim X2 insulin pump with Control-IQ technology 2.0 | Tandem Diabetes Care, Inc. | Type 1 Diabetes | 12/23 | 12/23 | | |
| Active, not recruiting | N/A | 200 | Europe, US | Omnipod 5 System | Insulet Corporation | Type 1 Diabetes | 09/23 | 01/25 | | |
| Completed | N/A | 343 | US | Omnipod 5 Automated Glucose Control System | Insulet Corporation, Jaeb Center for Health Research | Type2 Diabetes | 03/24 | 03/24 | | |
NCT05714059: Safety and Effectiveness of the MiniMed™ 780G System With DS5 CGM |
|
|
| Completed | N/A | 250 | US | Insulin Pump with Continuous Glucose Monitoring | Medtronic Diabetes | Type 1 Diabetes | 12/23 | 12/23 | | |
NCT06719531: SYNERGY PLUS: Evaluation of Next Generation Sensors (NGS) and Algorithm in Patients with Type 1 and Type 2 Diabetes |
|
|
| Not yet recruiting | N/A | 1500 | US | Continuous Glucose Monitoring | Medtronic Diabetes | Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus | 12/25 | 12/25 | | |
| Blevins, Thomas C |
NCT05706506: A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2) |
|
|
| Completed | 4 | 152 | US | Tirzepatide, LY3298176 | Eli Lilly and Company | Type 2 Diabetes, Diabetes Mellitus, Type 2 | 10/23 | 10/23 | | |
MKC-TI-193, NCT05904743: INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes |
|
|
| Completed | 4 | 141 | US | Afrezza, Technosphere Insulin, insulin degludec, Rapid-acting Insulin Analog, any FDA approved Rapid-acting Insulin Analog, Basal Insulin, any FDA approved Basal Insulin | Mannkind Corporation, Jaeb Center for Health Research | Diabetes Mellitus, Type 1 | 03/24 | 06/24 | | |
QWINT-4, NCT05462756 / 2021-005878-25: A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections |
|
|
| Completed | 3 | 730 | Europe, US, RoW | Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Lispro (U100), Humalog, Insulin Glargine (U100), Basaglar | Eli Lilly and Company, Eli Lilly and Company | Type 2 Diabetes, Type 2 Diabetes Treated With Insulin | 02/24 | 02/24 | | |
| Active, not recruiting | 3 | 75 | Europe, Canada, Japan, US, RoW | Plozasiran, ARO-APOC3, Placebo | Arrowhead Pharmaceuticals | Familial Chylomicronemia | 04/24 | 04/26 | | |
QWINT-5, NCT05463744: A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy |
|
|
| Completed | 3 | 692 | Europe, Japan, US, RoW | Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec | Eli Lilly and Company | Type 1 Diabetes, Diabetes | 05/24 | 05/24 | | |
ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities |
|
|
| Active, not recruiting | 3 | 3000 | Europe, Japan, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | Obesity, Overweight, Overweight or Obesity | 07/25 | 07/27 | | |
| Active, not recruiting | 3 | 1800 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Obesity, Cardiovascular Diseases | 01/26 | 02/26 | | |
| Completed | N/A | 343 | US | Omnipod 5 Automated Glucose Control System | Insulet Corporation, Jaeb Center for Health Research | Type2 Diabetes | 03/24 | 03/24 | | |
2IQP, NCT05785832: A Randomized Trial Evaluating Control-IQ Technology in Adults With Type 2 Diabetes |
|
|
| Completed | N/A | 319 | Canada, US | t:slim X2 insulin pump with Control-IQ technology 1.5 and Dexcom G6 CGM, Standard Therapy plus continuous glucose monitoring (CGM) | Tandem Diabetes Care, Inc., Jaeb Center for Health Research | Type 2 Diabetes Treated With Insulin | 09/24 | 09/24 | | |
| Harrison, Lindsay B |
| Terminated | 2b | 98 | Europe, Canada, US, RoW | EDP-305 1.5 mg, EDP-305, EDP-305 2 mg, Placebo | Enanta Pharmaceuticals, Inc, Enanta Pharmaceuticals, Inc. | Non-Alcoholic Steatohepatitis | 10/21 | 11/21 | | |
NCT05325294: Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adults and Pediatrics Utilizing Lyumjev® |
|
|
| Completed | N/A | 244 | US | MiniMed 780G System | Medtronic Diabetes, Eli Lilly and Company | Type 1 Diabetes | 01/24 | 01/24 | | |
| Ozer, Kerem |
MATILDA, NCT05632276: A Prospective, Multi Centre, Interventional, Non-comparator, Open Label Study to Demonstrate the Efficacy, Performance and Safety of ConvaFoam™ Silicone, ConvaFoam™ Border and ConvaFoam™ Non-Adhesive Dressings in the Management of Surgical and Traumatic Wounds |
|
|
| Completed | N/A | 54 | US | ConvaFoam, ConvaFoam Silicone, ConvaFoam Border, ConvaFoam Non Adhesive | ConvaTec Inc. | Surgical Wound, Trauma-related Wound | 03/24 | 03/24 | | |
NCT05805046: Study of Avelle™ Negative Pressure Wound Therapy (NPWT) System |
|
|
| Withdrawn | N/A | 59 | US | Negative Pressure Wound Therapy System, Avelle™ Negative Pressure Wound Therapy System | ConvaTec Inc. | Surgical Wound, Recent, Surgical Wound Leak, Dehiscence Wound, Trauma-related Wound | 10/23 | 10/23 | | |
| Casaubon, Luis |
NCT04809285: Use of the Guardian™ Connect System With Smart Connected Devices |
|
|
| Completed | N/A | 217 | US | Guardian™ Connect system, InPen™ Basal smart cap, smart insulin pens, and InPen™ Diabetes Management app | Medtronic Diabetes | Type 1 Diabetes Mellitus | 09/23 | 09/23 | | |
NCT05714059: Safety and Effectiveness of the MiniMed™ 780G System With DS5 CGM |
|
|
| Completed | N/A | 250 | US | Insulin Pump with Continuous Glucose Monitoring | Medtronic Diabetes | Type 1 Diabetes | 12/23 | 12/23 | | |
NCT05238142: In-Home Study with MiniMed™ 780G Pump Automated Control in Type 2-Evaluation of the AHCL System in Adults with Insulin-requiring Type 2 Diabetes |
|
|
| Active, not recruiting | N/A | 575 | US | MiniMed™ 780G Insulin Pump system | Medtronic Diabetes | Type 2 Diabetes Treated with Insulin | 01/25 | 02/25 | | |
| Garcia, Jose Luis |
NCT06261957: A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma |
|
|
| Recruiting | 3 | 412 | Europe, Canada, US, RoW | Salbutamol HFA-134a, Salbutamol HFA-152a | GlaxoSmithKline | Asthma | 04/25 | 04/25 | | |
| Completed | 3 | 806 | Europe, Canada, US, RoW | Placebo, Mepolizumab | GlaxoSmithKline, PPD DEVELOPMENT, LP | Pulmonary Disease, Chronic Obstructive | 08/24 | 08/24 | | |
|
|
|
|
|
| Completed | 2 | 203 | Europe, US, RoW | Olorofim, F901318 | F2G Biotech GmbH, Iqvia Pty Ltd | Invasive Fungal Infections | 02/23 | 02/23 | | |
NCT05312567: FP-101 Versus Placebo in the Treatment of Menopausal Vasomotor Symptoms |
|
|
| Completed | 2 | 105 | US | FP-101 | Fervent Pharmaceuticals, ICON plc | Vasomotor Symptoms, Menopause | 04/23 | 07/23 | | |
| Completed | 2 | 39 | Europe, US, RoW | RGH-706, Placebo | Gedeon Richter Plc., Gedeon Richter Plc, Chemical Works of Gedeon Richter Plc | Prader-Willi Syndrome | 04/24 | 04/24 | | |
| Terminated | 1/2 | 102 | Europe, US | Tazemetostat, EPZ-6438, E7438, IPN60200, Abiraterone/prednisone, Zytiga, Enzalutamide, Xtandi | Epizyme, Inc. | Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer | 11/24 | 11/24 | | |
|
|
| Terminated | N/A | 32 | Europe | dPR and FFR | Opsens, Inc. | Aortic Stenosis | 03/23 | 04/23 | | |
Mavericks, NCT05758545: Trial to Evaluate the Safety and Effectiveness of Treatment With COMS One Device in Subjects With Diabetic Foot Ulcers |
|
|
| Recruiting | N/A | 450 | US | COMS One device, Concurrent Optical and Magnetic Stimulation, Sham device | Piomic Medical, NAMSA | Diabetic Foot Ulcer | 06/27 | 06/27 | | |
| Reed, John H |
NCT05706506: A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2) |
|
|
| Completed | 4 | 152 | US | Tirzepatide, LY3298176 | Eli Lilly and Company | Type 2 Diabetes, Diabetes Mellitus, Type 2 | 10/23 | 10/23 | | |
ATTAIN-2, NCT05872620: A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes |
|
|
| Active, not recruiting | 3 | 1500 | Europe, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | Obesity, Overweight, Type 2 Diabetes | 08/25 | 08/25 | | |
OPTI-2, NCT06238778: Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec |
|
|
| Recruiting | 2 | 230 | US | HDV-Lispro, HDV-L, Lispro, LIS | Diasome Pharmaceuticlas, Inc. | Diabetes Mellitus, Type 1 | 06/25 | 12/25 | | |
| Completed | 2 | 265 | Europe, Canada, US, RoW | INV-202, None applicable, Placebo | Inversago Pharma Inc., Worldwide Clinical Trials | Diabetic Kidney Disease | 08/24 | 09/24 | | |
NCT04809285: Use of the Guardian™ Connect System With Smart Connected Devices |
|
|
| Completed | N/A | 217 | US | Guardian™ Connect system, InPen™ Basal smart cap, smart insulin pens, and InPen™ Diabetes Management app | Medtronic Diabetes | Type 1 Diabetes Mellitus | 09/23 | 09/23 | | |
| Completed | N/A | 343 | US | Omnipod 5 Automated Glucose Control System | Insulet Corporation, Jaeb Center for Health Research | Type2 Diabetes | 03/24 | 03/24 | | |
NCT05325294: Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adults and Pediatrics Utilizing Lyumjev® |
|
|
| Completed | N/A | 244 | US | MiniMed 780G System | Medtronic Diabetes, Eli Lilly and Company | Type 1 Diabetes | 01/24 | 01/24 | | |
NCT05714059: Safety and Effectiveness of the MiniMed™ 780G System With DS5 CGM |
|
|
| Completed | N/A | 250 | US | Insulin Pump with Continuous Glucose Monitoring | Medtronic Diabetes | Type 1 Diabetes | 12/23 | 12/23 | | |
NCT02748018: Multi-center Trial in Adult and Pediatric Patients With Type 1 Diabetes Using Hybrid Closed Loop System and Control at Home |
|
|
| Active, not recruiting | N/A | 280 | Europe, Canada, US, RoW | 670G and 770G Insulin Pump, Subject's Current Diabetes Therapy | Medtronic Diabetes | Type 1 Diabetes | 03/25 | 06/25 | | |
NCT06273124: Investigational Extended Wear Insulin Infusion Set in People With Type 1 Diabetes |
|
|
| Completed | N/A | 260 | US | SteadiSet Extended Wear Infusion Set | Tandem Diabetes Care, Inc., Jaeb Center for Health Research | Type1diabetes | 12/24 | 12/24 | | |
NCT05238142: In-Home Study with MiniMed™ 780G Pump Automated Control in Type 2-Evaluation of the AHCL System in Adults with Insulin-requiring Type 2 Diabetes |
|
|
| Active, not recruiting | N/A | 575 | US | MiniMed™ 780G Insulin Pump system | Medtronic Diabetes | Type 2 Diabetes Treated with Insulin | 01/25 | 02/25 | | |
NCT05224258: Evaluation of the MiniMed™ 780G System in Type 1 Adult and Pediatric Subjects Utilizing Insulin Fiasp® |
|
|
| Completed | N/A | 240 | Canada, US, RoW | MiniMed 780G System | Medtronic Diabetes | Type 1 Diabetes | 06/24 | 06/24 | | |
NCT06452914: Clinical Outcomes Related to Treatment of Distal Symmetric Polyneuropathy Using Semiconductor Embedded Therapeutic Socks |
|
|
| Not yet recruiting | N/A | 80 | NA | Semiconductor Embedded Therapeutic Socks, Placebo Socks | Endocrine Research Solutions, INCREDIWEAR HOLDINGS, INC. | Diabetic Neuropathy | 06/25 | 06/25 | | |
NCT06719531: SYNERGY PLUS: Evaluation of Next Generation Sensors (NGS) and Algorithm in Patients with Type 1 and Type 2 Diabetes |
|
|
| Not yet recruiting | N/A | 1500 | US | Continuous Glucose Monitoring | Medtronic Diabetes | Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus | 12/25 | 12/25 | | |
| Tapia, Jessica |
OPTI-2, NCT06238778: Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec |
|
|
| Recruiting | 2 | 230 | US | HDV-Lispro, HDV-L, Lispro, LIS | Diasome Pharmaceuticlas, Inc. | Diabetes Mellitus, Type 1 | 06/25 | 12/25 | | |
NCT04809285: Use of the Guardian™ Connect System With Smart Connected Devices |
|
|
| Completed | N/A | 217 | US | Guardian™ Connect system, InPen™ Basal smart cap, smart insulin pens, and InPen™ Diabetes Management app | Medtronic Diabetes | Type 1 Diabetes Mellitus | 09/23 | 09/23 | | |
| Completed | N/A | 343 | US | Omnipod 5 Automated Glucose Control System | Insulet Corporation, Jaeb Center for Health Research | Type2 Diabetes | 03/24 | 03/24 | | |
NCT05325294: Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adults and Pediatrics Utilizing Lyumjev® |
|
|
| Completed | N/A | 244 | US | MiniMed 780G System | Medtronic Diabetes, Eli Lilly and Company | Type 1 Diabetes | 01/24 | 01/24 | | |
NCT05714059: Safety and Effectiveness of the MiniMed™ 780G System With DS5 CGM |
|
|
| Completed | N/A | 250 | US | Insulin Pump with Continuous Glucose Monitoring | Medtronic Diabetes | Type 1 Diabetes | 12/23 | 12/23 | | |
NCT02748018: Multi-center Trial in Adult and Pediatric Patients With Type 1 Diabetes Using Hybrid Closed Loop System and Control at Home |
|
|
| Active, not recruiting | N/A | 280 | Europe, Canada, US, RoW | 670G and 770G Insulin Pump, Subject's Current Diabetes Therapy | Medtronic Diabetes | Type 1 Diabetes | 03/25 | 06/25 | | |
NCT06273124: Investigational Extended Wear Insulin Infusion Set in People With Type 1 Diabetes |
|
|
| Completed | N/A | 260 | US | SteadiSet Extended Wear Infusion Set | Tandem Diabetes Care, Inc., Jaeb Center for Health Research | Type1diabetes | 12/24 | 12/24 | | |
NCT05238142: In-Home Study with MiniMed™ 780G Pump Automated Control in Type 2-Evaluation of the AHCL System in Adults with Insulin-requiring Type 2 Diabetes |
|
|
| Active, not recruiting | N/A | 575 | US | MiniMed™ 780G Insulin Pump system | Medtronic Diabetes | Type 2 Diabetes Treated with Insulin | 01/25 | 02/25 | | |
NCT06719531: SYNERGY PLUS: Evaluation of Next Generation Sensors (NGS) and Algorithm in Patients with Type 1 and Type 2 Diabetes |
|
|
| Not yet recruiting | N/A | 1500 | US | Continuous Glucose Monitoring | Medtronic Diabetes | Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus | 12/25 | 12/25 | | |
NCT04502316: Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence (REBALANCE Registry) |
|
|
| Recruiting | N/A | 5000 | US | Barostim™ System | CVRx, Inc. | Heart Failure | 06/28 | 06/28 | | |
| Cooper, Alison |
| Suspended | 3 | 675 | Europe, Canada, US, RoW | Metformin DR, ANJ900, MetDR, Metformin IR, Metformin DR Placebo, Metformin IR placebo | Anji Pharma | Diabetes Mellitus, Type 2 | 12/23 | 06/24 | | |
| Lopez, Emmanuel |
OPTI-2, NCT06238778: Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec |
|
|
| Recruiting | 2 | 230 | US | HDV-Lispro, HDV-L, Lispro, LIS | Diasome Pharmaceuticlas, Inc. | Diabetes Mellitus, Type 1 | 06/25 | 12/25 | | |
NCT06273124: Investigational Extended Wear Insulin Infusion Set in People With Type 1 Diabetes |
|
|
| Completed | N/A | 260 | US | SteadiSet Extended Wear Infusion Set | Tandem Diabetes Care, Inc., Jaeb Center for Health Research | Type1diabetes | 12/24 | 12/24 | | |
| Hosford, Jennifer |
NCT05743244: Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D) |
|
|
| Recruiting | 2 | 78 | US | Abrocitinib 200 MG Oral Tablet, CIBINQO, Ritlecitinib, Placebo | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Pfizer | Diabetes Mellitus, Type 1 | 06/26 | 06/27 | | |
TOPPLE T1D, NCT04279613: A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041 |
|
|
| Completed | 1 | 47 | US | NNC0361-0041, Placebo | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Novo Nordisk A/S | Type I Diabetes | 08/23 | 04/24 | | |
NCT06719531: SYNERGY PLUS: Evaluation of Next Generation Sensors (NGS) and Algorithm in Patients with Type 1 and Type 2 Diabetes |
|
|
| Not yet recruiting | N/A | 1500 | US | Continuous Glucose Monitoring | Medtronic Diabetes | Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus | 12/25 | 12/25 | | |
| Montoya, Dawn |
NCT05714059: Safety and Effectiveness of the MiniMed™ 780G System With DS5 CGM |
|
|
| Completed | N/A | 250 | US | Insulin Pump with Continuous Glucose Monitoring | Medtronic Diabetes | Type 1 Diabetes | 12/23 | 12/23 | | |
| Chen, Jean |
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk |
|
|
| Active, not recruiting | 3 | 2749 | Europe, US, RoW | Orforglipron, LY3502970, Insulin Glargine | Eli Lilly and Company | Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease | 09/25 | 01/26 | | |
| Active, not recruiting | 3 | 15374 | Europe, Canada, Japan, US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Obesity, Overweight | 10/27 | 10/27 | | |
OPTI-2, NCT06238778: Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec |
|
|
| Recruiting | 2 | 230 | US | HDV-Lispro, HDV-L, Lispro, LIS | Diasome Pharmaceuticlas, Inc. | Diabetes Mellitus, Type 1 | 06/25 | 12/25 | | |
ZONE, NCT05762107: A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes |
|
|
| Recruiting | 2 | 186 | Canada, US | Placebo, ZT-01, 7 mg, ZT-01, 15 mg, ZT-01, 22 mg | Zucara Therapeutics Inc. | Type 1 Diabetes Mellitus with Hypoglycemia | 06/25 | 07/25 | | |
NCT06273124: Investigational Extended Wear Insulin Infusion Set in People With Type 1 Diabetes |
|
|
| Completed | N/A | 260 | US | SteadiSet Extended Wear Infusion Set | Tandem Diabetes Care, Inc., Jaeb Center for Health Research | Type1diabetes | 12/24 | 12/24 | | |
NCT06719531: SYNERGY PLUS: Evaluation of Next Generation Sensors (NGS) and Algorithm in Patients with Type 1 and Type 2 Diabetes |
|
|
| Not yet recruiting | N/A | 1500 | US | Continuous Glucose Monitoring | Medtronic Diabetes | Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus | 12/25 | 12/25 | | |
| Recruiting | N/A | 925 | US | Blood glucose meter, Eversense CGM System | Senseonics, Inc. | Diabetes | 03/26 | 03/26 | | |
| Armstrong, Chloe |
MKC-TI-193, NCT05904743: INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes |
|
|
| Completed | 4 | 141 | US | Afrezza, Technosphere Insulin, insulin degludec, Rapid-acting Insulin Analog, any FDA approved Rapid-acting Insulin Analog, Basal Insulin, any FDA approved Basal Insulin | Mannkind Corporation, Jaeb Center for Health Research | Diabetes Mellitus, Type 1 | 03/24 | 06/24 | | |
